Anesthesiology Doctors in Sharon, PA Accepting Medicare
5 Anesthesiology doctors found. Showing 1 - 5
 Dr. Shaun Hennon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 740 E State St, Sharon, PA 16146 Phone: 724-983-7310 Fax: 724-983-2797 |
Dr. Donald Lewis Person, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 740 E State St, Sharon, PA 16146 Phone: 724-983-7310 Fax: 724-983-2797 |
 Dr. Sonia B. Mokgethi, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 740 E State St, Sharon, PA 16146 Phone: 724-983-7310 Fax: 724-983-2797 |
Dr. Frederick Gottlieb Kurz, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 740 E State St, Sharon, PA 16146 Phone: 724-983-7310 Fax: 724-983-2797 |
Emil A. Maurer Jr., M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 740 E State St, Sharon, PA 16146 Phone: 724-983-7310 Fax: 724-983-2797 |
News Archive
Rudd proposes that GP's take on care of diabetics
In a bid to ease the strain caused by diabetes on the hospitals, Australian Prime Minister, Kevin Rudd has proposed that GP's take on care of diabetics. For every diabetes patient that a GP handles, the government will pay the doctor $1200 a year to cover day-to-day costs. Each GP will receive up to $10,800 annually based on performance.
Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.
MiMedx Group's revenue increases 108% to $40.8 million in first quarter 2015
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the first quarter of 2015.
FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis
FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).
› Verified 2 days ago
Internal Medicine
Psychiatry & Neurology
Anesthesiology
Pediatrics
Emergency Medicine
Family Medicine
Radiology
Surgery
Pathology
Obstetrics & Gynecology